Optimi Health's stock is trading higher after the company announced a significant strategic expansion into a new psychedelic compound.
- On June 12, Optimi announced it has secured a supply of naturally derived ibogaine from two sources and will begin development of finished drug products.
- The company plans to produce encapsulated formulations in 50mg and 100mg dosage strengths at its GMP-certified facility in British Columbia, with development starting this summer.
- This initiative aims to support growing demand for ibogaine from research institutions and regulated access programs exploring its therapeutic potential for various neurological and psychiatric conditions.